Sanofi, Regeneron get boost in PCSK9 rivalry; AstraZeneca pulls Lynparza from CDF eval; Aetna hasn't decided on Gilead vs. AbbVie hep C meds;

> Sanofi ($SNY) and Regeneron ($REGN) got a boost against rival Amgen ($AMGN) as new study data show that the companies' PCSK9 cholesterol-lowering antibody alirocumab is effective when given once a month. Story

> AstraZeneca ($AZN) withdrew its cancer drug Lynparza from England's Cancer Drugs Fund (CDF) evaluation process, one day after the fund announced that it would cut its list of covered meds. Story

> Aetna CEO Mark Bertolini said the company has not yet decided whether to cover Gilead Sciences ($GILD) or AbbVie's ($ABBV) hepatitis C drug, but is "actively working" on reaching a decision. More

> U.K. cost watchdog NICE gave a thumbs-down to Dendreon's ($DNDN) prostate cancer drug Provenge for the second time this year. Article

> Israel's MediSafe raised $6 million in funding to support development of its mobile platform for drug adherence. More

And Finally... Want to look smarter? Study shows eye contact and eyeglasses work, but five-dollar words don't. Report

 

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.